Status:
COMPLETED
A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study
Lead Sponsor:
Ilaria Colombo
Collaborating Sponsors:
Institute for Research in Biomedicine
Ente Ospedaliero Cantonale, Bellinzona
Conditions:
Covid19
Cancer
Eligibility:
All Genders
Brief Summary
This is a single centre prospective observational study to assess the immune response to SARS-CoV-2 vaccines in cancer patients receiving active treatment or in follow-up at the IOSI and in non-cancer...
Detailed Description
This study will be conducted on 7 cohorts of cancer patients and 1 cohort of non-cancer subjects (age and gender matched) with a sample size of 30 patients in each cohort: All enrolled patients will ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male of Female age at least 18 years
- Patients with a diagnosis of malignancy (solid tumors or hematological malignancies) according to the defined cohorts. Only for cohorts 1-7
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Absence of known immune deficiency (other than cancer for cohorts 1-7)
- Ability to understand the patient information and study consent. Signed and dated written informed consent must be available before performing any study-related procedure
- Willing and able to comply with the study procedures.
- Willing to receive an mRNA anti-SARS-CoV-2 vaccine.
Exclusion
Key Trial Info
Start Date :
February 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 21 2023
Estimated Enrollment :
177 Patients enrolled
Trial Details
Trial ID
NCT04800146
Start Date
February 25 2021
End Date
March 21 2023
Last Update
March 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland, 6500